Trials / Completed
CompletedNCT05381948
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 161 (actual)
- Sponsor
- EyePoint Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
Detailed description
This study is evaluating the 2 doses of EYP-1901 against aflibercept in a randomized study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EYP-1901 | Intravitreal Injection |
| DRUG | Aflibercept 2mg/0.05mL Inj,Oph | Intravitreal Injection |
Timeline
- Start date
- 2022-06-30
- Primary completion
- 2023-11-29
- Completion
- 2024-04-24
- First posted
- 2022-05-19
- Last updated
- 2025-10-15
- Results posted
- 2025-10-02
Locations
67 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05381948. Inclusion in this directory is not an endorsement.